Drugs / MEDI6469
MEDI6469
also known as
9b12, a murine igg1 antibody
Monoclonal antibody targets TNFRSF4 via activation
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02559024 | Mar 2016 → Oct 2018 | colorectal cancer | Providence Health & Services | Terminated | No outcome recorded |
| Phase 1 | NCT02274155 | Nov 2014 → Sep 2017 | head and neck cancer | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01862900 | Apr 2012 → May 2016 | breast cancer, metastatic malignant neoplasm | Providence Health & Services | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02205333 | Aug 2014 → Apr 2016 | aggressive B-cell non-Hodgkin lymphoma, cancer | MedImmune LLC | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI6469 | “Here we describe the results from a phase Ib clinical trial (NCT02274155) in which 17 patients with locally advanced head and neck squamous cell carcinoma (HNSCC) received a...” PMID 33594075 ↗ Feb 2021 |
| Known as | 9b12, a murine igg1 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109531 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL2109531 ↗1“murine anti-human OX40 agonist antibody (MEDI6469)” PMID 33594075 ↗ Feb 2021 |
| Modality | Monoclonal antibody | “Monoclonal Antibody to OX40 (MEDI6469)” NCT01862900 ↗ |
| Route | Intravenous | “MEDI6469 is administered at 0.4 mg/kg IV over 60 minutes” NCT01862900 ↗ |
| Target | TNFRSF4 | “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL2109531 ↗ |